Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers

Background: Vicagrel is a novel anti-platelet drug and hydrolyzed to the same intermediate as clopidogrel via esterase, instead of CYP2C19. Here we report the first clinical trial on the tolerability, pharmacokinetics and pharmacodynamics of different doses of vicagrel, and comparison with clopidogr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Li, Xiaojiao, Liu, Cai, Zhu, Xiaoxue, Wei, Haijing, Zhang, Hong, Chen, Hong, Chen, Guiling, Yang, Deming, Sun, Hongbin, Shen, Zhenwei, Zhang, Yifan, Li, Wei, Yang, Jin, Liu, Yongqiang, Lai, Xiaojuan, Gong, Yanchun, Liu, Xuefang, Li, Yongguo, Zhong, Dafang, Niu, Junqi, Liu, Bin, Ding, Yanhua
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2018
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6019484/
https://ncbi.nlm.nih.gov/pubmed/29973877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.00643
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados